Mintu Turakhia to Join Executive Leadership Team at iRhythm Under Planned Leave of Absence
Mintu Turakhia MD, MAS, Professor of Medicine (Cardiovascular Medicine), will take a planned leave of absence from Stanford to join iRhythm Technologies, Inc. as their new Chief Medical Officer and Chief Scientific Officer.
One of the earliest and most successful companies originating in the Stanford Biodesign program, iRhythm is perhaps best known for its cardiac monitoring device invented here. The new leadership role will enable Turakhia to combine his clinical and scientific interests in cardiac electrophysiology, pragmatic clinical trials, digital health, wearables, and artificial intelligence and pursue his passion to transform cardiovascular care.
The projects, programs, and grants that Turakhia has led at Stanford will continue to flourish and support faculty, trainees, and staff. The Center for Digital Health (CDH) in the Department of Medicine has thrived under his leadership, securing a large funding portfolio, seminal research publications, public-private partnerships, and an innovative health technology postdoctoral fellowship program. Clark Seninger MBA will continue to serve as its executive director and work with a CDH leadership team that includes Dr. Fatima Rodriguez, Dr. Euan Ashley, Dr. Paul Wang, Dr. Alex Sandhu, Dr. Raj Dash, and others.
Turakhia has made an extraordinary impact at Stanford, not only in areas of science, teaching, and patient care, but in building large sustainable programs. He has mentored over 50 trainees, many of whom are still in the Department of Medicine. During his leave, he will continue to serve in volunteer teaching and mentoring roles and he will also continue a limited clinical practice at the VA Palo Alto.
Department of Medicine Chair Bob Harrington expressed his full support for this next step in Turakhia's career, "I am thrilled for Mintu to have this incredible opportunity at iRhythm to apply his vast experience with patient care and unparalleled leadership in digital health and heart rhythm care at Stanford to the ever evolving, critical landscape of cardiovascular medicine. We will look forward to his return."